Swollen Knee Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Swollen Knee Treatment Market Trends and Insights

Aging-Related Growth in Knee Osteoarthritis

Knee osteoarthritis affected 33.6% of U.S. adults aged 65 years and older in 2025, and the rate reached 42.1% among women in this age group. Symptomatic rates rose from 7% at age 45 to 12% at age 60, which extends demand beyond the oldest patient groups^{[1]American Academy of Family Physicians, “Knee and Hip Osteoarthritis,” FP Essentials, aafp.org.}. High-SDI countries carried an age-standardized prevalence of 4,656.7 per 100,000 people, but middle-SDI countries have greater room for diagnosis and care. Incidence peaked at ages 50 to 64, bringing more working-age patients into the swollen knee treatment market. This patient group favors treatment in the swollen knee treatment market that can preserve mobility and reduce time away from work. It also supports demand for therapies and recovery protocols that can delay late-stage care.

Rising Obesity-Associated Knee Disease

Obesity and hyperlipidemia were associated with more severe synovitis and poorer functional outcomes after total knee arthroplasty in patients with knee osteoarthritis. Higher obesity classes were also associated with greater health care use and knee osteoarthritis medication consumption. Eli Lilly reported that retatrutide reduced WOMAC pain scores by up to 75.8% and produced average weight loss of 28.7% at 68 weeks in people with obesity and knee osteoarthritis. The results place weight management alongside orthopedic treatment for an overlapping patient population. Better weight control can improve joint mechanics before surgical care is needed. This link broadens the treatment pathway addressed by the swollen knee treatment market.

Expansion of Minimally Invasive and Outpatient Care

Robotic-assisted total knee arthroplasty accounted for 8.5% of the United States utilization in 2020 and is projected to represent 70.1% of 2.63 million annual procedures by 2030. Patients receiving robotic-assisted procedures had shorter hospital stays of 1.9 days compared with 2.8 days for other procedures. The same study reported lower complication rates for robotic-assisted treatment. Same-day discharge shifts activity toward analgesic management, remote rehabilitation, and outpatient physical therapy. Japan expanded insurance coverage in 2024 for femoral distal osteotomy and arthroscopic meniscal stabilization, adding joint-preserving options. These care settings can redirect spending within the swollen knee treatment market away from longer inpatient episodes.

Longer-Acting and Single-Injection Therapies

Single-injection hyaluronic acid regimens were associated with a 13-month longer delay to total knee arthroplasty compared with no hyaluronic acid use. They also extended the time to surgery by 4 months beyond multi-injection regimens. GC Wellbeing received approval in South Korea for Healroad Once Inj., a single-dose hyaluronic acid product, increasing local competitive pressure. Biosplice submitted an NDA for lorecivivint in January 2026 after 11 clinical trials reported pain, function, and medial joint-space-width findings. Longer dosing intervals could strengthen the value proposition for intra-articular injections. A successful approval would alter pricing expectations within the swollen knee treatment market.

Safety Risks and Restricted Use of Long-Term Analgesics

Chronic NSAID use carries cardiovascular, gastrointestinal, and renal risks, leading clinical guidance to favor the lowest effective dose for the shortest period. The Hong Kong College of Orthopedic Surgeons recommends topical NSAIDs as first-line management for knee osteoarthritis and oral products as second-line treatment. Germany's DGOU guideline in May 2025 also emphasized limited NSAID dosing and removed glucosamine from its recommendations. Meta-analyses reported limited benefit for non-tramadol opioids and discontinuation rates of 22%, compared with 15% for controls. These restrictions place pressure on branded oral analgesics and opioid-containing products. The result limits pharmaceutical growth in the swollen knee treatment market.

Reimbursement Uncertainty for Viscosupplementation and Biologics

CMS reduced the 2025 Physician Fee Schedule conversion factor by 2.93%, from USD 33.29 to USD 32.35. The reduction affects physician-office and outpatient economics for hyaluronic acid injections. Medicare LCD Article A56157 has created audit and claim-denial exposure for viscosupplementation providers. Medicare Advantage plans can require prior authorization and prior corticosteroid treatment for these products. Coverage for bone marrow aspirate concentrate, adipose-derived cell therapies, and platelet-rich plasma remains inconsistent across U.S. payers and European assessment bodies. South Carolina Blues classified orthopedic stem-cell applications as investigational in 2024.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment: Accessories Gain Ground as Digital Tools Reshape Conservative Management

Pharmaceuticals held 44.28% of the swollen knee treatment market share in 2025, supported by NSAIDs, corticosteroids, and hyaluronic acid viscosupplements. These products remained common first- and second-line options for knee swelling. Within pharmaceuticals, single-injection regimens are shifting value toward cross-linked and ultra-high-molecular-weight hyaluronic acid products. Evidence that these products may delay surgery supports their use before surgical intervention. The disease-modifying osteoarthritis drug category had seen repeated clinical failures. Biosplice submitted its lorecivivint NDA to the FDA in January 2026. The submission could mark the first major advance in this category in nearly 28 years. It could also change how pharmaceutical treatment is positioned in the swollen knee treatment industry.

Accessories are projected to grow at a 7.80% CAGR through 2031, making them the fastest-growing treatment category. Smart and sensor-enabled supports lead to this expansion. Wearable-based telerehabilitation also produced greater neuromuscular adaptation than conventional physiotherapy^{[2]A. M. Kauppila et al., “Efficacy of the mHealth-Based Exercise Intervention re.flex,” JMIR mHealth and uHealth, mhealth.jmir.org.}. Unloader and functional braces retain substantial use in osteoarthritis. Post-operative and rehabilitative braces are also expanding as total knee arthroplasty moves to ambulatory settings. Surgical treatment retains volume through replacement and arthroscopy. Robotic approaches can increase capital-equipment spending and support implant standardization. This mix gives accessories a larger role in the swollen knee treatment market.

By Indication: Osteoarthritis Leads While Sports Injuries Accelerate

Osteoarthritis accounted for 44.03% of indication revenues in 2025. The condition had a global patient population of 374.7 million, sustaining its position throughout the forecast period. The United States direct annual costs per patient ranged from USD 3,719 to USD 4,518. The indication uses pharmaceuticals, therapy, accessories, and surgical treatment. Broader coverage of joint-preserving procedures in Japan and Germany can extend intervention before total replacement. Rheumatoid arthritis was the second-largest indication. It is supported by corticosteroid and biologic prescribing. It also benefits from established reimbursement pathways in the United States and Europe. These patterns keep osteoarthritis at the center of the swollen knee treatment market.

Sports and traumatic injuries are forecast to grow at a 7.82% CAGR through 2031. Organized sports participation and greater awareness of acute knee effusion management support this rate. Aspiration, arthrocentesis, physical therapy, and meniscal or ligament reconstruction benefit from this demand. Smart support can also monitor recovery for active patients. The FDA approved MACI Arthro in August 2024 for arthroscopic delivery in adults with cartilage defects up to 4 cm². The expanded label addressed 20,000 additional patients annually and increased Vericel's target surgeon base from 5,000 to 7,000. Gout, crystal arthropathies, bursitis, tendinopathy, infection, and septic arthritis remained smaller but distinct sources of demand. They mainly require aspiration, corticosteroid injections, or antimicrobial pharmaceutical care. This diversity broadens activity in the swollen knee treatment industry.

By Route of Administration: Procedural Care Gains Weight

Oral administration held 44.28% of the route-of-administration revenue in 2025. NSAIDs, non-NSAID analgesics, and opioid prescriptions supported its broad use in primary and secondary care. Guidance restricting dose and duration is limiting oral treatment growth. The DGOU guideline directed prescribing toward limited NSAID use and exercise-based management. Similar care approaches favor topical and intra-articular alternatives. This shifts revenue from oral products toward procedural and surgical care in the swollen knee treatment market. The change occurs within pharmaceuticals as well as across the wider care pathway. It makes the swollen knee treatment market less dependent on prolonged oral drug use.

Procedural and surgical administration is projected to grow at an 8.26% CAGR through 2031. The route includes corticosteroid, hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrate, and regenerative injections. It also includes arthroplasty, arthroscopy, and cartilage repair. A meta-analysis of 38 studies covering 83,888 outpatient joint arthroplasties reported lower odds of readmission, emergency department use, and complications for day-case surgery. The respective odds ratios were 0.83, 0.62, and 0.70 compared with inpatient care. This setting can make surgery more accessible and cost-efficient. Intravenous and intramuscular routes continue to serve septic arthritis, rheumatoid arthritis flares, and post-operative analgesia. Their growth is expected to track the overall swollen knee treatment market rather than exceed it.

By End User: Hospitals Retain Scale While Orthopedic Clinics Add Volume

Hospitals accounted for 47.35% of end-user revenue in 2025. They remain the principal setting for total knee replacement, complex revision procedures, intravenous drug administration, and inpatient rehabilitation. Research published in 2026 documented a large movement of primary total knee arthroplasty from inpatient to outpatient facilities in the United States. This movement reduces hospital volume for elective orthopedic procedures. Hospitals are responding through investments in robotic surgical platforms. The strategy seeks to retain procedure volumes and strengthen relationships with surgeons. Ambulatory surgical centers are gaining elective procedure volume. CMS set a 2.9% update for 2025 outpatient and ambulatory surgical center payments. These factors preserve hospital relevance in the swollen knee treatment market while altering the site of care.

Orthopedic clinics are forecast to grow at a 7.78% CAGR through 2031. Clinics handle outpatient corticosteroid, hyaluronic acid, and platelet-rich plasma injections. They also provide brace fitting, physical-therapy-adjacent services, and post-operative monitoring. These activities transfer naturally from hospital settings in the swollen knee treatment market. Rheumatology clinics serve a separate demand base in rheumatoid arthritis, gout, and crystal arthropathy. Biologic and disease-modifying antirheumatic drug prescribing remains concentrated in those clinics. Digital operating tools target the administrative workload across outpatient musculoskeletal practice. Such tools can affect workflow efficiency as well as procedure capacity. This supports clinic participation across the swollen knee treatment market.

Geography Analysis

North America held 41.85% of the swollen knee treatment market share in 2025. High procedural intensity, established reimbursement for surgery and injections, and an aging population support the region. The United States's knee osteoarthritis prevalence reached 33.6% among adults aged 65 years and older. The shift toward ambulatory surgical centers lowers hospital elective volume while raising contributions from ambulatory centers and clinics.

Europe was the second-largest regional market in 2025. Germany, the United Kingdom, and France carried the highest absolute osteoarthritis patient volumes in the region. DGOU issued an evidence-based gonarthrosis guideline in May 2025 that removed glucosamine and electrotherapy from recommendations. The policy directs care toward exercise-based treatment, followed by pharmacological or surgical options where needed.

Asia-Pacific is projected to grow at a 7.88% CAGR through 2031, the fastest rate among regions. Japan and South Korea have high age-standardized knee osteoarthritis prevalence, supported by policy and product changes. Japan added femoral distal osteotomy and arthroscopic meniscal stabilization to national insurance coverage in 2024. South Korea saw GC Wellbeing's 2024 approval for Healroad Once Inj., adding competition in single-injection hyaluronic acid treatment. China drives absolute volume growth in the swollen knee treatment market through health care infrastructure development. India and Australia, along with the smaller Middle East and Africa and South American markets, extend the swollen knee treatment market opportunity through investment, manufacturing incentives, reimbursement, and population aging.